Privi Speciality Chemicals Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Record quarter, volume-led: Total income grew 26% YoY and 20% QoQ, driven by 17% volume growth and 8-10% price increases across flagship and newly introduced products.
• Margins hit an all-time high: EBITDA margin reached 26.83% for the quarter, powered by innovation, byproduct value addition, de-bottlenecking, and backward integration.
• The balance sheet is strengthening: Net working capital improved to 124 days, hitting the stated target, while net debt fell by ₹44 crore to ₹1,020 crore.
• A 15-month product pipeline is loading: Management flagged a robust pipeline of volume-driven and specialty molecules, with bio-waste-derived products from Privi Biotechnology now in early commercialization.
• What to watch next quarter: Whether the 6,000-metric-ton capacity expansion, due by end-December, translates into the promised growth from January, and if the 24-26% margin band holds as the new baseline.

Performance & Margin Drivers

• Volume and price both fired: H1 revenue rose on a 17% volume increase and an 8-10% price increase, with demand broadening across top-15 blenders, five major FMCG companies, smaller fragrance houses, and Indian customers.
• Record margins built on structural levers: The 26.83% EBITDA margin reflects continuous innovation, value addition through byproducts, tight expense control, de-bottlenecking of critical processes, and backward integration advantages that competitors cannot easily replicate.
• Phase-1 expansion arrived early: Part of the expansion was completed ahead of schedule, partially fueling the quarter's growth, with the balance to finish by FY26-end and take total capacity from 48,000 to 54,000 metric tons.
• Capacity is already tight: Utilization ran at 90-92% in H1, so the additional 6,000 metric tons due by end-December must come online to relieve the constraint and enable growth from January onward.
• State incentives are now a durable margin tailwind: ₹5.59 crore from Gujarat and ₹3.41 crore from Maharashtra were booked in H1 as operating income, recognized against past CAPEX. Management expects these to continue and is confident of securing Ultra Mega status, which would extend the incentive period to 20 years.

Narayan S. Iyer: "This is actually an operating income with the company for the next 15 years, and we are very confident that we will also get the status of the Ultra Mega."

Product Pipeline & Diversification

• A 15-month wave of launches is coming: The pipeline mixes typical Privi products (large volume, gross margin 30%+) with about 10 specialty molecules that carry high value and high margin. All are expected to be operational and contributing within 12 to 15 months.
• The strategy is to build a broad body, not a long tail: Management aims to reduce any single product's contribution to roughly 10% maximum, targeting about 10 products that each contribute meaningfully to the mix. It declined to name specific molecules, saying it is working on the "entire body" of the portfolio.
• Biotechnology is moving from lab to plant: Privi Biotechnology, the wholly owned R&D subsidiary, has commercialized some products in the last month, scaling from grams to tens of kilograms. Management claims the company is among the first few globally to produce aroma ingredients from bio-waste, a differentiator for sustainability-conscious export markets and FMCG customers.
• New products sell to the same customers: The majority of new products will be sold to existing relationships, making the diversification a share-of-wallet story rather than a new-customer acquisition challenge.

Sanjeev Patil: "We would be among the top, I mean, first few companies globally to have these products coming from bio-waste."

Demand & Competitive Position

• Fragrance is gaining wallet share: Increased demand from all top-15 blenders, five major FMCG companies (P&G, Henkel, Reckitt), and smaller fragrance houses substantiates management's belief that consumers are moving toward fragrance-oriented products across categories.
• China Plus One is real and accelerating: Customers from Europe and developed nations are looking for sustainable players. Privi's backward integration lets it offer stable pricing for longer periods with back-to-back offerings, a structural advantage in this shift.
• Market share held despite tariff headwinds: The company maintained and increased market share in key products even as global tariff uncertainty created headwinds, a sign of competitive resilience.
• October run rate held: No downfall was seen in October, with contracts in place to maintain the run rate, though management declined to discuss pricing strategy for the October-December contract renewal cycle.

Sanjeev Patil: "We are not just working on two wheels or two engines. Not double engine. We are trying to add many more engines so that the growth perpetuates."

Balance Sheet & Capital Efficiency

• Working capital target achieved: Net working capital improved from 136 days in March 2025 to 124 days in September 2025, landing inside the 120-125 day target. Management expects to sustain this level.
• Debt is declining: Net debt reduced by ₹44 crore to ₹1,020 crore, with the working capital improvement contributing to the deleveraging.
• Return on capital is rising without heavy CAPEX: Process intensification and de-bottlenecking have steadily improved returns with minimal incremental capital, a pattern management expects to continue.
• Raw material security is not a constraint: No availability problems are foreseen for planned growth over the next three to five years, removing a key risk for the expansion plan.

The 5K, 1K Vision

• The ambition is to more than double the business: Management is on track to reach ₹5,000 crore revenue and ₹1,000 crore EBITDA over the next three to five years, driven by internal growth metrics, CAPEX over the next 24 months, the existing 54,000 metric ton capacity base, and a mix of volume-driven and specialty products.
• The 20% CAGR is the baseline: The company has maintained a 20% CAGR for two decades and expects the same number going forward, implying upward of 20% revenue growth as the planning assumption.
• JV PRIGIV is a future contributor: The joint venture is ramping up well, with meaningful contributions expected in a few years, though no quantification was provided.
• Biotechnology inputs will take years to fully land: Inputs from Privi Biotechnology will be implemented in the parent company over the next three to four years, aligning with the outer edge of the 5K, 1K timeline.

Sanjeev Patil: "We have a very robust pipeline of products which will be operational over the next 15 months or so, which is a mix of products which are typical of Privi product range, which is reasonably large volume and gross margin which are in the range of 30% and more."

Guidance & Commitments

Key Metrics